|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee
Submitted 28 November 2007 ; accepted in final form 9 April 2008
Dimethyl amiloride (DMA) enhances insulin secretion in the pancreatic β-cell. DMA also enhances time-dependent potentiation (TDP) and enables TDP to occur in situations where it is normally absent. As we have demonstrated before, these effects are mediated in part through inhibition of neuronal nitric oxide synthase (nNOS), resulting in increased availability of arginine. Thus both DMA and arginine have the potential to correct the secretory defect in diabetes by enabling or enhancing TDP. In the current study we have demonstrated the ability of these agents to improve blood glucose homeostasis in three mouse models of type 2 diabetes. The pattern of TDP under different conditions indicates that inhibition of NOS is not the only mechanism through which DMA exerts its positive effects. Thus we also have explored another possible mechanism through which DMA enables/enhances TDP, via the activation of mitochondrial
-ketoglutarate dehydrogenase.
pancreatic islets; β-cell memory; insulin secretion
This article has been cited by other articles:
![]() |
A. CHATZIGEORGIOU, A. HALAPAS, K. KALAFATAKIS, and E. KAMPER The Use of Animal Models in the Study of Diabetes Mellitus In Vivo, March 1, 2009; 23(2): 245 - 258. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |